Risdiplam

Brand names: Evrysdi · Active ingredient: Risdiplam

In short: EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Forms & strengthsEVRYSDI for oral solution: 60 mg as a light yellow, pale yellow, yellow, greyish yellow, greenish yellow, or light green powder for constitution. …
LabelGenentech, Inc.
Label updatedNov 05, 2026

What is Risdiplam used for?

EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Risdiplam dosage

EVRYSDI is administered orally once daily with or without food at approximately the same time each day. The recommended dosage is determined by age and body weight . EVRYSDI tablets are available for patients prescribed the 5 mg dose.

Age and Body Weight | Recommended Daily Dosage | Dosage Form

Less than 2 months of age | 0.15 mg/kg | EVRYSDI for Oral Solution

2 months to less than 2 years of age | 0.2 mg/kg

2 years of age and older weighing less than 20 kg | 0.25 mg/kg

2 years of age and older weighing 20 kg or more | 5 mg | EVRYSDI for Oral SolutionorEVRYSDI Tablet

It is recommended that a healthcare provider discuss with the patient or caregiver how to prepare the prescribed daily dose prior to administration of the first dose [see Instructions for Use for EVRYSDI for Oral Solution and EVRYSDI Tablets and Patient Information].

EVRYSDI for Oral Solution

In infants who are breastfed, EVRYSDI for oral solution can be administered before or after breastfeeding. EVRYSDI cannot be mixed with formula or milk.

Instruct patients or caregivers to administer the dose using the reusable oral syringe provided.

EVRYSDI for oral solution must be taken immediately after it is drawn up into the oral syringe. If EVRYSDI is not taken within 5 minutes, EVRYSDI should be discarded from the oral syringe, and a new dose should be prepared.

Instruct patients to drink water after taking EVRYSDI for oral solution to ensure the drug has been completely swallowed.

EVRYSDI for oral solution can be administered via a nasogastric or gastrostomy tube. The tube should be flushed with water after delivering EVRYSDI for oral solution .

EVRYSDI Tablets

Swallow EVRYSDI tablets whole with water. Do not chew, cut, or crush the tablets.

Alternatively, the EVRYSDI tablet can also be dispersed in one teaspoon (5 mL) of room temperature non-chlorinated drinking water (e.g., filtered water). EVRYSDI tablets must not be dispersed in any liquid other than non-chlorinated drinking water. Do not expose the prepared dispersion to sunlight. Swirl the small cup gently for up to 3 minutes until fully mixed (though some particles will remain). Administer the dispersed tablet immediately. To ensure no particles are left in the small cup, refill it with at least one tablespoon (15 mL) of non-chlorinated drinking water, swirl, and administer immediately again.

EVRYSDI must be taken immediately after it is dispersed in non-chlorinated drinking water. Discard the prepared dispersion if it is not used within 10 minutes of adding non-chlorinated drinking water.

The dispersed EVRYSDI tablet can be administered via a nasogastric or gastrostomy tube that is 8 French or higher. Flush the tube with the non-chlorinated drinking water [at least one tablespoon (15 mL)] used to rinse the dispersion cup

. …

How to take Risdiplam — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Pregnancy and Fetal Risk

Inform pregnant women and women of reproductive potential that, based on animal studies, EVRYSDI may cause fetal harm .

Discuss with women of childbearing age whether they are pregnant, might be pregnant, or are trying to become pregnant.

Advise women of childbearing potential to use effective contraception during treatment with EVRYSDI and for at least 1 month after stopping EVRYSDI.

Advise a female patient to immediately inform the prescriber if she is pregnant or planning to become pregnant .

Pregnancy Registry

Encourage patients to enroll in the EVRYSDI Pregnancy Registry if they become pregnant while taking EVRYSDI .

Potential Effects on Male Fertility

Advise male patients that their fertility may be compromised while on treatment with EVRYSDI .

Instructions for Preparation of Oral Solution

Advise patients/caregivers to ensure that EVRYSDI oral solution is in liquid form when received from the pharmacy. …

Warnings & precautions

Do not take this medicine if: None.

Risdiplam side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.

In clinical trials including patients with infantile-onset SMA, later-onset SMA, and pre-symptomatic SMA, a total of 491 patients (51% female, 74% Caucasian) were exposed to EVRYSDI for up to a median duration of 48.1 months (range: 0.6 to 63.4 months), with 231 patients receiving treatment for more than 24 months. At the time of first EVRYSDI dose, 90 (18%) patients were 18 years and older, 119 (24%) were 12 years to less than 18 years, 189 (39%) were 2 years to less than 12 years, 67 (14%) 2 months to less than 2 years, and 26 (5%) were less than 2 months. Additionally, safety was evaluated in 11 neonates with SMA aged less than 20 days at first dose (55% female, 73% not Hispanic or Latino) who were exposed to EVRYSDI for up to a median duration of 26 days (range: 7 to 29 days), including 3 patients less than 7 days of age who had a median duration of exposure of 8 days (range: 7 to 10 days).

Clinical Trial in Later-Onset SMA

The safety of EVRYSDI for later-onset SMA is based on data from a randomized, double-blinded, placebo-controlled study (Study 2 Part 2) in patients with SMA Type 2 or 3 (n = 180) . The patient population in Study 2 Part 2 ranged in age from 2 to 25 years at the time of the first dose. …

Drug interactions

Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K , such as metformin. Avoid coadministration of EVRYSDI with MATE substrates. If coadministration cannot be avoided, monitor for drug-related toxicities and consider dosage reduction of the coadministered drug (based on the labeling of that drug) if needed.

About this medicine

EVRYSDI for oral solution and EVRYSDI tablets for oral use contain risdiplam, which is a survival of motor neuron 2 (SMN2)-directed RNA splicing modifier.

The chemical name of risdiplam is 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8 dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido-4H-[1,2-a]pyrimidin-4-one. Risdiplam has a molecular weight of 401.46 g/mol. Risdiplam demonstrates pH-dependent aqueous solubility; the greatest solubility is at low pH, and solubility decreases with increasing pH. Risdiplam has a pKa1 of 3.78 (base) and pKa2 of 6.62 (base).

The molecular formula of risdiplam is C22H23N7O and the chemical structure is shown below.

EVRYSDI for oral solution is supplied as a powder in an amber glass bottle. Each bottle contains 60 mg of risdiplam. The inactive ingredients of EVRYSDI are: ascorbic acid, disodium edetate dihydrate, isomalt, mannitol, polyethylene glycol 6000, sodium benzoate, strawberry flavor, sucralose, and tartaric acid.

The powder is constituted with purified water to yield 60 mg/80 mL (0.75 mg/mL) of risdiplam after constitution . …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID eceb9a99-7191-4be5-87c3-0102707cf98e. Read the full official label on DailyMed.